Patents by Inventor Ferenc Boldog

Ferenc Boldog has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230313187
    Abstract: The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce cultured mammalian cells for therapeutic or diagnostic purposes.
    Type: Application
    Filed: September 3, 2021
    Publication date: October 5, 2023
    Applicant: DNA TWOPOINTO INC.
    Inventors: Jeremy MINSHULL, Maggie LEE, Varsha SITARAMAN, Oren BESKE, Ferenc BOLDOG
  • Publication number: 20230295625
    Abstract: The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce- cultured mammalian cells for therapeutic of diagnostic purposes.
    Type: Application
    Filed: December 29, 2022
    Publication date: September 21, 2023
    Inventors: Jeremy MINSHULL, Ferenc BOLDOG, Varsha SITARAMAN, Maggie LEE
  • Publication number: 20220112500
    Abstract: The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce cultured mammalian cells for therapeutic or diagnostic purposes.
    Type: Application
    Filed: November 4, 2021
    Publication date: April 14, 2022
    Applicant: DNA TWOPOINTO INC.
    Inventors: JEREMY MINSHULL, FERENC BOLDOG, VARSHA SITARAMAN, MAGGIE LEE
  • Patent number: 11162102
    Abstract: The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce cultured mammalian cells for therapeutic or diagnostic purposes.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: November 2, 2021
    Assignee: DNA TWOPOINTO INC.
    Inventors: Jeremy Minshull, Maggie Lee, Varsha Sitaraman, Ferenc Boldog
  • Publication number: 20200362344
    Abstract: The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce cultured mammalian cells for therapeutic or diagnostic purposes.
    Type: Application
    Filed: May 11, 2020
    Publication date: November 19, 2020
    Inventors: Jeremy Minshull, Maggie Lee, Varsha Sitaraman, Ferenc Boldog
  • Publication number: 20180010108
    Abstract: The present invention provides, among other things, methods and compositions for production of recombinant I2S protein with improved potency and activity using cells co-express I2S and FGE protein. In some embodiments, cells according to the present invention are engineered to simultaneously over-express recombinant I2S and FGE proteins. Cells according to the invention are adaptable to various cell culture conditions. In some embodiments, cells of the present invention adaptable to a large-scale suspension serum-free culture.
    Type: Application
    Filed: July 14, 2017
    Publication date: January 11, 2018
    Inventors: Ferenc Boldog, Michael Heartlein
  • Patent number: 9719074
    Abstract: The present invention provides, among other things, methods and compositions for production of recombinant I2S protein with improved potency and activity using cells co-express I2S and FGE protein. In some embodiments, cells according to the present invention are engineered to simultaneously over-express recombinant I2S and FGE proteins. Cells according to the invention are adaptable to various cell culture conditions. In some embodiments, cells of the present invention adaptable to a large-scale suspension serum-free culture.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: August 1, 2017
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Ferenc Boldog, Michael Heartlein
  • Publication number: 20160053238
    Abstract: The present invention provides, among other things, methods and compositions for production of recombinant I2S protein with improved potency and activity using cells co-express I2S and FGE protein. In some embodiments, cells according to the present invention are engineered to simultaneously over-express recombinant I2S and FGE proteins. Cells according to the invention are adaptable to various cell culture conditions. In some embodiments, cells of the present invention adaptable to a large-scale suspension serum-free culture.
    Type: Application
    Filed: August 21, 2015
    Publication date: February 25, 2016
    Inventors: Ferenc Boldog, Michael Heartlein
  • Patent number: 9150841
    Abstract: The present invention provides, among other things, methods and compositions for production of recombinant I2S protein with improved potency and activity using cells co-express I2S and FGE protein. In some embodiments, cells according to the present invention are engineered to simultaneously over-express recombinant I2S and FGE proteins. Cells according to the invention are adaptable to various cell culture conditions. In some embodiments, cells of the present invention adaptable to a large-scale suspension serum-free culture.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 6, 2015
    Inventors: Ferenc Boldog, Michael Heartlein
  • Publication number: 20140004097
    Abstract: The present invention provides, among other things, methods and compositions for large-scale production of recombinant I2S protein using suspension culture of mammalian cells in serum-free medium. In particular, the present invention uses mammalian cells co-express a recombinant I2S protein and a formylglycine generating enzyme (FGE).
    Type: Application
    Filed: March 14, 2013
    Publication date: January 2, 2014
    Inventors: Chun Zhang, Ferenc Boldog
  • Publication number: 20140004593
    Abstract: The present invention provides, among other things, methods and compositions for production of recombinant I2S protein with improved potency and activity using cells co-express I2S and FGE protein. In some embodiments, cells according to the present invention are engineered to simultaneously over-express recombinant I2S and FGE proteins. Cells according to the invention are adaptable to various cell culture conditions. In some embodiments, cells of the present invention adaptable to a large-scale suspension serum-free culture.
    Type: Application
    Filed: March 14, 2013
    Publication date: January 2, 2014
    Inventors: Ferenc Boldog, Michael Heartlein
  • Patent number: 7141549
    Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Grant
    Filed: February 8, 2005
    Date of Patent: November 28, 2006
    Inventors: Peter Mezes, Luca Rastelli, John Herrmann, John MacDougall, Haihong Zhong, Stacie Casman, Ferenc Boldog, Richard Shimkets, Linda Gorman, Andrew Eisen, Steven Spaderna, Corine Vernet, Constance Berghs, Kimberly Spytek, Vincent DiPippo, Bryan Zerhusen, John Peyman, Karen Ellerman, David Stone, William Grosse, John Alsobrook, II, Denise Lepley, Daniel Rieger, Catherine Burgess, Shlomit Edinger, Edward Voss, Charles Miller
  • Publication number: 20060234257
    Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Application
    Filed: February 8, 2006
    Publication date: October 19, 2006
    Inventors: Uriel Malyankar, Xiaojia Guo, Ferenc Boldog, Nikolai Khramstsov
  • Publication number: 20060094647
    Abstract: The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotide sequences and the FGF-CX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.
    Type: Application
    Filed: November 6, 2001
    Publication date: May 4, 2006
    Inventors: Michael Jeffers, Richard Shimkets, Sudhirdas Prayaga, Ferenc Boldog, Meijia Yang, Catherine Burgess, Elma Fernandes, Beth Rittman, Juliette Shimkets, William LaRochelle, Henri Lichenstein
  • Publication number: 20060084054
    Abstract: The present invention provides novel isolated polynucleotides and small molecule target polypeptides encoded by the polynucleotides. Antibodies that immunospecifically bind to a novel small molecule target polypeptide or any derivative, variant, mutant or fragment of that polypeptide, polynucleotide or antibody are disclosed, as are methods in which the small molecule target polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states. More specifically, the present invention discloses methods of using recombinantly expressed and/or endogenously expressed proteins in various screening procedures for the purpose of identifying therapeutic antibodies and therapeutic small molecules associated with diseases. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Application
    Filed: June 4, 2003
    Publication date: April 20, 2006
    Inventors: John Alsobrook, David Anderson, Jason Baumgartner, Constance Berghs, Ferenc Boldog, Catherine Burgess, Stacie Casman, Elina Catterton, Mohanraj Dhanabal, Shlomit Edinger, Karen Ellerman, Seth Ettenberg, Esha Gangolli, Valerie Gerlach, Linda Gorman, William Grosse, Erik Gunther, Xiaojia Guo, Vladimir Gusev, John Herrmann, Weizhen Ji, Ramesh Kekuda, Nikolai Khramtsov, William LaRochelle, Li Li, Hongping Liang, Kenneth Low, John MacDougall, Timothy Maclachlan, Uriel Malyankar, Kelly McQueeney, Amanda Mezick, Charles Miller, Isabelle Millet, Muralidhara Padigaru, Meera Patturajan, John Peyman, Xiaozhong Qian, Luca Rastelli, Daniel Rieger, Mark Rothenberg, Suresh Shenoy, Richard Shimkets, Glennda Smithson, Kimberly Spytek, David Stone, Sujatha Sukumaran, Edward Szekeres, Corine Vernet, Edward Voss, Adam Wolenc, Mei Zhong, Haihong Zhong
  • Publication number: 20060063200
    Abstract: Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Application
    Filed: February 2, 2005
    Publication date: March 23, 2006
    Applicant: CuraGen Corporation
    Inventors: David Anderson, Jason Baumgartner, Ferenc Boldog, Stacie Casman, Shlomit Edinger, Esha Gangolli, Valerie Gerlach, Linda Gorman, Xiaojia Guo, Tord Hjalt, Ramesh Kekuda, Li Li, John MacDougall, Uriel Malyankar, Isabelle Millet, Muralidhara Padigaru, Meera Patturajan, Carol Pena, Luca Rastelli, Richard Shimkets, David Stone, Kimberly Spytek, Corine Vernet, Edward Voss, Bryan Zerhusen
  • Publication number: 20060009634
    Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Application
    Filed: December 21, 2004
    Publication date: January 12, 2006
    Inventors: Ramesh Kekuda, John Alsobrook, Velizar Tchernev, Xiaohong Liu, Kimberly Spytek, Meera Patturajan, William Grosse, Denise Lepley, Catherine Burgess, Corine Vernet, Li Li, Linda Gorman, Shlomit Edinger, Paul Sciore, Karen Ellerman, Uriel Malyankar, Mark Rothenberg, David Stone, Ferenc Boldog, Xiaojia Guo, Suresh Shenoy, David Anderson, Muralidhara Padigaru, Raymond Taupier, Charles Miller, Andrew Eisen
  • Publication number: 20060003323
    Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. Vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same are also included. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Application
    Filed: June 3, 2003
    Publication date: January 5, 2006
    Inventors: John Alsobrook, Enrique Alvarez, David Anderson, Ferenc Boldog, Stacie Casman, Elina Catterton, Andrei Chapoval, Julie Crabtree-Bokor, Shlomit Edinger, Karen Ellerman, Seth Ettenberg, Esha Gangolli, Valerie Gerlach, Linda Gorman, Erik Gunther, Xiaojia (Sasha) Guo, Vladimir Gusev, John Herrmann, Weizhen Ji, Ramesh Kekuda, Li Li, Xiaohong Liu, John MacDougall, Timothy Machlachlan, Uriel Malyankar, Amanda Mezick, Isabelle Millet, Vishnu Mishra, Muralidhara Padigaru, Meera Patturajan, Carol Pena, John Peyman, Debasish Raha, Luca Rastelli, Daniel Rieger, Mark Rothenberg, Paul Sciore, Suresh Shenoy, Richard Shimkets, Glennda Smithson, Kimberly Spytek, David Stone, Corine Vernet, Edward Voss, Mei Zhong, Hiahong Zhong
  • Publication number: 20050208514
    Abstract: The present invention generally relates to nucleic acids, proteins, and antibodies. The invention relates more particularly to nucleic acid molecules, proteins, and antibodies of Fibroblast Growth Factor-20 (FGF-20), or its fragments, derivatives, variants, homologs, analogs, or a combination thereof.
    Type: Application
    Filed: November 3, 2004
    Publication date: September 22, 2005
    Inventors: John Alsobrook, Ferenc Boldog, Michael Jeffers, William LaRochelle, Denise Lepley, Henri Lichenstein, Richard Shimkets, Meijia Yang, Marie Ruiz-Martinez, Galina Chernaya, Muralidhara Padigaru, Sudhirdas Prayaga, Mei Zhong
  • Publication number: 20050170380
    Abstract: The present invention provides novel isolated SECX polynucleotides and the membrane-associated or secreted polypeptides encoded by the SECX polynucleotides. Also provided are the antibodies that immunospecifically bind to a SECX polypeptide or any derivative, variant, mutant or fragment of the SECX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the SECX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.
    Type: Application
    Filed: October 21, 2004
    Publication date: August 4, 2005
    Applicant: CuraGen Corporation
    Inventors: Elma Fernandes, Corine Vernet, Richard Shimkets, David Anderson, Muralidhara Padigaru, Ferenc Boldog, Li Li, Suresh Shenoy, Stacie Casman, Luca Rastelli